Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives
Lars Asphaug(Oslo University Hospital), Bjørn Naume(Norwegian Cancer Society), Cecilie E. Kiserud(Oslo University Hospital), Bård Mannsåker(Nordland Hospital), Oluf Dimitri Røe(Norwegian University of Science and Technology), Alina Carmen Porojnicu(Norwegian Cancer Society), Gry Aarum Geitvik(Oslo University Hospital), Helle Kristine Skjerven(Vestre Viken Hospital Trust), H.E.G. Russnes(Oslo University Hospital), Elin Borgen(Oslo University Hospital), Pernilla Turunen Olsson(Innlandet Hospital Trust), Bjørnar Gilje(Stavanger University Hospital), Jon Lømo(Oslo University Hospital), Lars A. Akslen(University of Bergen), Sunil Xavier Raj(St Olav's University Hospital), Torgunn Kursetgjerde(Sahlgrenska University Hospital), Hege O. Ohnstad(Oslo University Hospital), Berit Gravdehaug(Akershus University Hospital), Beate Boge(Hospital of Southern Norway), Silje Songe-Møller(University Hospital of North Norway), Magdalena A Vestlid(Telemark Hospital), Egil Støre Blix(University Hospital of North Norway), Anita Langerød(Oslo University Hospital), Anette Heie(Haukeland University Hospital), Elin Mortensen(University Hospital of North Norway), Emiel A. M. Janssen(Stavanger University Hospital), Mette Brekke(St Olav's University Hospital), Ragnhild Sørum Falk(Oslo University Hospital)
Cited by 2
Related Papers
The Life History of 21 Breast Cancers
|Cell|2012|1.5k
Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas
|Clinical Cancer Research|2009|310
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282